Edition:
United States

ArQule Inc (ARQL.O)

ARQL.O on Consolidated Issue listed on NASDAQ Global Market

1.14USD
22 Sep 2017
Change (% chg)

$0.02 (+1.79%)
Prev Close
$1.12
Open
$1.14
Day's High
$1.15
Day's Low
$1.11
Volume
109,829
Avg. Vol
153,550
52-wk High
$1.82
52-wk Low
$0.92

Latest Key Developments (Source: Significant Developments)

Arqule Q2 loss per share $0.10
Friday, 4 Aug 2017 07:00am EDT 

Aug 4 (Reuters) - Arqule Inc :Arqule reports second quarter 2017 financial results.Q2 loss per share $0.10.Q2 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.Arqule Inc - ‍at june 30, 2017, company had a total of approximately $31 million in cash, equivalents and marketable securities​.Arqule Inc - ‍revenues for quarter ended june 30, 2017, were zero compared with revenues of $1.1 million for quarter ended June 30, 2016​.  Full Article

Arqule initiates early-stage trial of ARQ 092
Wednesday, 7 Jun 2017 07:00am EDT 

June 7 (Reuters) - Arqule Inc :Arqule announces first patient dosed in company sponsored phase 1/2 trial of akt inhibitor, ARQ 092, for rare overgrowth diseases.Phase 1/2 trial with co's akt inhibitor, arq 092, will enroll patients with overgrowth diseases driven by pi3k/akt1 pathway.  Full Article

Arqule Q1 loss per share $0.11
Wednesday, 3 May 2017 07:00am EDT 

May 3 (Reuters) - Arqule Inc :Arqule reports first quarter 2017 financial results.Q1 loss per share $0.11.Q1 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.Arqule inc- revenues for quarter ended march 31, 2017, were zero compared with revenues of $1.2 million for quarter ended march 31, 2016.  Full Article

ArQule receives clearance of IND application from the FDA for proprietary reversible BTK inhibitor, ARQ 531
Tuesday, 11 Apr 2017 07:00am EDT 

ArQule Inc : ArQule receives clearance of investigational new drug application from the FDA for proprietary reversible BTK inhibitor, ARQ 531 . ArQule Inc - ArQule plans to initiate a phase 1A/B dose escalation and signal generation trial by Q3 of 2017 . ArQule - Upon completion of phase 1a trial, plans to begin phase 1B trial in number of expansion cohorts .ArQule Inc - Expansion cohorts will include patients with C481S mutation who are refractory to other therapies.  Full Article

Arqule trial did not meet its primary endpoint of progression free survival
Monday, 27 Mar 2017 07:00am EDT 

Arqule Inc : Trial did not meet its primary endpoint of progression free survival (pfs). . There were no new safety issues observed in trial .Its partner, Kyowa Hakko Kirin, announced top-line results of JET-HCC phase 3 trial of Tivantinib in Japan.  Full Article

Arqule posts Q4 loss per share of $0.10
Tuesday, 7 Mar 2017 07:00am EST 

Arqule Inc : Arqule reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.10 . Q4 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S . Sees FY 2017 loss per share $0.42 to $0.45 . Arqule inc- for 2017, Arqule expects net use of cash to range between $25 and $27 million . Arqule expects to end 2017 with between $18 and $20 million in cash and marketable securities .FY 2017 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S.  Full Article

Daiichi Sankyo and ArQule's carcinoma drug failed in late-stage trial
Friday, 17 Feb 2017 06:00am EST 

ArQule Inc - : Daiichi Sankyo and Arqule announce the completion of the metiv-hcc phase 3 study of tivantinib in second-line treatment of met-overexpressing hepatocellular carcinoma . Study of tivantinib in hepatocellular carcinoma (hcc) did not meet its primary endpoint of improving overall survival .Primary endpoint of study is overall survival.  Full Article

Arqule enters into capital on demand sales agreement with Jonestrading Institutional Services LLC on Oct. 25
Wednesday, 26 Oct 2016 06:18am EDT 

Arqule Inc : Arqule- On October 25, 2016, co entered into a capital on demand!" sales agreement with Jonestrading Institutional Services LLC - sec filing .Arqule- May sell from time to time through agent shares of co's common stock, par value $0.01 per share with an aggregate sales price of up to $30 million.  Full Article

Arqule Inc files for mixed shelf of upto $100 million - SEC filing
Friday, 2 Sep 2016 08:07am EDT 

Arqule Inc : Files for mixed shelf of upto $100 million - SEC filing Source: (http://bit.ly/2bJGGEw) Further company coverage: [ARQL.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Arqule Q2 loss per share $0.07
Wednesday, 3 Aug 2016 07:00am EDT 

Arqule Inc : Q2 loss per share $0.07 . Q2 earnings per share view $-0.08 -- Thomson Reuters I/B/E/S . Arqule reports second quarter 2016 financial results . Q2 revenue $1.072 million versus i/b/e/s view $1.1 million .Q2 earnings per share view $-0.08, revenue view $1.1 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Arqule Inc CEO Paolo Pucci​ buys 19,156 shares of co's common stock on Sept 5

* Arqule Inc CEO Paolo Pucci​ reports purchase of 19,156 shares of co's common stock on Sept 5 at average price of $1.14 per share - SEC filing Source text: (http://bit.ly/2j4eXnk) Further company coverage: